




RealRate

PHARMACEUTICAL 2015

Talpheria INC
Rank 165 of 274

AcelRx
Pharmaceuticals, Inc.



The relative strengths and weaknesses of Talpheria INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Talpheria INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 39% points. The greatest weakness of Talpheria INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 51% points.

The company's Economic Capital Ratio, given in the ranking table, is 237%, being 17% points below the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	76,298
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	13,731
Liabilities, Non-Current	18,046
Other Assets	331
Other Compr. Net Income	-5.0
Other Expenses	2,639
Other Liabilities	8,014
Other Net Income	6,935
Other Revenues	5,217
Property and Equipment	9,818
Research and Development	24,520
Selling, General and Administrative Expense	18,346

Output Variable	Value in 1000 USD
Assets	86,447
Liabilities	39,791
Expenses	45,505
Revenues	5,217
Stockholders Equity	46,656
Net Income	-33,353
Comprehensive Net Income	-33,356
BaseVar	91,950
ECR before LimitedLiability	108%
Economic Capital Ratio	237%